Halozyme Therapeutic (HALO)

$77.93 +1.45 (1.90%)
Market Cap 8.43B
Revenue (ttm) 1.02B
Net Income (ttm) 444.09M
EPS (ttm) N/A
PE Ratio 13.79
Forward PE 9.99
Profit Margin 43.74%
Debt to Equity Ratio 3.00
Volume 2,602,500
Avg Vol 2,082,116
Day's Range N/A - N/A
Shares Out 117.60M
Stochastic %K 91%
Beta 0.94
Analysts Sell
Price Target $79.50

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Punit
Punit Feb. 4 at 9:14 PM
$HALO he's foooooking backkkkkkk
0 · Reply
Doozio
Doozio Feb. 4 at 6:17 PM
May da $HALO protect YO during 🐒🍌🧠⏰♾️ over macro jabronis. 🦄👑s over RIVNs.
10 · Reply
WAJeff
WAJeff Feb. 3 at 3:00 PM
Had 1/2 $HALO sell at $76, the ath is $79.50
0 · Reply
Sean29md
Sean29md Feb. 3 at 1:22 AM
$HALO Merck's earnings call is tomorrow. Don't be surprised if they announce an MDASE licensing deal with Halozyme. Analysts like Morgan Stanley are talking about Keytruda life cycle management being the most important topic to be addressed at the CC tomorrow. With the court injunction against Merck banning Keytruda SC in Germany, there is tremendous time pressure for a deal before more EU courts follow the German example. Per Helen: A) 3 of Halozyme’s MDASE patents are immune from PGR attempts by Merck and B) the amino acid sequence in AltB-4 used by Merck is public for anyone to see and this sequence is identical to MDASE sequences. Put all this info in your AI app of your choice and ask to handicap the outcomes. You will see that Merck is highly likely to sign a licensing deal with Halozyme or lose in courts.
1 · Reply
Swahilipete
Swahilipete Feb. 3 at 12:13 AM
$HALO please talk about this stock. It is mostly owned by tutes. If retailers got in the price will rise! The biotech is making money hand over fist!
1 · Reply
Sean29md
Sean29md Jan. 29 at 9:03 PM
$HALO Very constructive action today. Cornnie Johnson's comical rating could not keep the price down even for one day.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 7:25 PM
$HALO Share Price: $72.66 Contract Selected: Sep 18, 2026 $75 Calls Buy Zone: $5.27 – $6.51 Target Zone: $9.19 – $11.23 Potential Upside: 65% ROI Time to Expiration: 231 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 6:11 PM
$HALO just caught a bid — and the market liked what it saw. 🚀 Shares jumped nearly 4% after Halozyme Therapeutics delivered strong preliminary 2025 results that beat expectations, while management also lifted its 2026 outlook. That combo is getting investor attention fast. See what’s driving the optimism here 👉 https://www.zacks.com/stock/news/2825515/halo-rises-nearly-4-on-strong-2025-preliminary-data-and-2026-guidance?cid=sm-stocktwits-2-2825515-teaser-31028&ADID=SYND_STOCKTWITS_TWEET_2_2825515_TEASER_31028
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 5:11 PM
$HALO climbs nearly 4% after beating 2025 expectations and upping 2026 guidance! 🚀 📈 Preliminary 2025 revenues hit $1.39B-$1.40B, surpassing previous guidance and Zacks Consensus Estimate. 🔮 2026 sales guidance raised to $1.71B-$1.81B, with royalties set to exceed $1B in 2026, a year early. Discover the full growth story here 👉 https://www.zacks.com/stock/news/2825515/halo-rises-nearly-4-on-strong-2025-preliminary-data-and-2026-guidance?cid=sm-stocktwits-2-2825515-body-31029&ADID=SYND_STOCKTWITS_TWEET_2_2825515_BODY_31029
0 · Reply
Sean29md
Sean29md Jan. 29 at 4:28 PM
$HALO part 3: Clearly, Cornnie Johnson did not learn a lesson the first time she was swimming against the current of market participants, other analysts and her own company’s Asset Management Portfolio Manager. Remember her comical analysis today. She will be embarrassed once again when we start trading in $80’s and $90. http://tipranks.com/news/the-fly/h… http://cnbc.com/video/2025/11/…
0 · Reply
Latest News on HALO
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth

Feb 2, 2026, 11:43 PM EST - 1 day ago

Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript

Jan 28, 2026, 12:12 PM EST - 7 days ago

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Jan 28, 2026, 6:30 AM EST - 7 days ago

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Jan 20, 2026, 4:05 PM EST - 15 days ago

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Jan 8, 2026, 8:00 AM EST - 27 days ago

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 4 weeks ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Dec 18, 2025, 7:00 AM EST - 6 weeks ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)

Dec 15, 2025, 4:06 AM EST - 7 weeks ago

Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)

Jim Lang Elected to Halozyme's Board of Directors

Dec 8, 2025, 4:05 PM EST - 2 months ago

Jim Lang Elected to Halozyme's Board of Directors

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Dec 4, 2025, 2:22 PM EST - 2 months ago

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Dec 4, 2025, 1:26 PM EST - 2 months ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 3:43 PM EST - 2 months ago

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 2 months ago

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Nov 18, 2025, 8:50 AM EST - 2 months ago

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

Nov 17, 2025, 7:00 AM EST - 2 months ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUS

The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 3 months ago

The Big 3: OKLO, HALO, V

OKLO V

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Nov 7, 2025, 8:30 AM EST - 3 months ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 6, 2025, 11:37 PM EST - 3 months ago

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 5, 2025, 4:05 PM EST - 3 months ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 8:16 PM EST - 3 months ago

Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Nov 3, 2025, 4:01 PM EST - 3 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Halozyme Just Bought Its Next Decade Of Growth

Oct 23, 2025, 1:17 PM EDT - 3 months ago

Halozyme Just Bought Its Next Decade Of Growth

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 21, 2025, 8:30 AM EDT - 3 months ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 10, 2025, 8:35 AM EDT - 4 months ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 3:22 PM EDT - 4 months ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:16 AM EDT - 4 months ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Oct 1, 2025, 7:00 AM EDT - 4 months ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:29 AM EDT - 5 months ago

Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Sep 4, 2025, 5:34 PM EDT - 5 months ago

Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 5 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 5 months ago

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 5:45 AM EDT - 6 months ago

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Aug 5, 2025, 4:01 PM EDT - 6 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 23, 2025, 11:36 AM EDT - 7 months ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 22, 2025, 8:30 AM EDT - 7 months ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Jul 14, 2025, 4:33 PM EDT - 7 months ago

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 7 months ago

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jun 20, 2025, 1:15 PM EDT - 8 months ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 28, 2025, 8:30 AM EDT - 9 months ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 9 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:15 PM EDT - 9 months ago

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 6, 2025, 4:01 PM EDT - 9 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 5, 2025, 5:15 PM EDT - 9 months ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 9 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 8:30 AM EDT - 10 months ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 28, 2025, 7:30 AM EDT - 10 months ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 24, 2025, 8:30 AM EDT - 10 months ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 10, 2025, 6:15 PM EDT - 10 months ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 9, 2025, 8:45 AM EDT - 10 months ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Apr 7, 2025, 9:29 AM EDT - 10 months ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Punit
Punit Feb. 4 at 9:14 PM
$HALO he's foooooking backkkkkkk
0 · Reply
Doozio
Doozio Feb. 4 at 6:17 PM
May da $HALO protect YO during 🐒🍌🧠⏰♾️ over macro jabronis. 🦄👑s over RIVNs.
10 · Reply
WAJeff
WAJeff Feb. 3 at 3:00 PM
Had 1/2 $HALO sell at $76, the ath is $79.50
0 · Reply
Sean29md
Sean29md Feb. 3 at 1:22 AM
$HALO Merck's earnings call is tomorrow. Don't be surprised if they announce an MDASE licensing deal with Halozyme. Analysts like Morgan Stanley are talking about Keytruda life cycle management being the most important topic to be addressed at the CC tomorrow. With the court injunction against Merck banning Keytruda SC in Germany, there is tremendous time pressure for a deal before more EU courts follow the German example. Per Helen: A) 3 of Halozyme’s MDASE patents are immune from PGR attempts by Merck and B) the amino acid sequence in AltB-4 used by Merck is public for anyone to see and this sequence is identical to MDASE sequences. Put all this info in your AI app of your choice and ask to handicap the outcomes. You will see that Merck is highly likely to sign a licensing deal with Halozyme or lose in courts.
1 · Reply
Swahilipete
Swahilipete Feb. 3 at 12:13 AM
$HALO please talk about this stock. It is mostly owned by tutes. If retailers got in the price will rise! The biotech is making money hand over fist!
1 · Reply
Sean29md
Sean29md Jan. 29 at 9:03 PM
$HALO Very constructive action today. Cornnie Johnson's comical rating could not keep the price down even for one day.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 7:25 PM
$HALO Share Price: $72.66 Contract Selected: Sep 18, 2026 $75 Calls Buy Zone: $5.27 – $6.51 Target Zone: $9.19 – $11.23 Potential Upside: 65% ROI Time to Expiration: 231 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 6:11 PM
$HALO just caught a bid — and the market liked what it saw. 🚀 Shares jumped nearly 4% after Halozyme Therapeutics delivered strong preliminary 2025 results that beat expectations, while management also lifted its 2026 outlook. That combo is getting investor attention fast. See what’s driving the optimism here 👉 https://www.zacks.com/stock/news/2825515/halo-rises-nearly-4-on-strong-2025-preliminary-data-and-2026-guidance?cid=sm-stocktwits-2-2825515-teaser-31028&ADID=SYND_STOCKTWITS_TWEET_2_2825515_TEASER_31028
0 · Reply
ZacksResearch
ZacksResearch Jan. 29 at 5:11 PM
$HALO climbs nearly 4% after beating 2025 expectations and upping 2026 guidance! 🚀 📈 Preliminary 2025 revenues hit $1.39B-$1.40B, surpassing previous guidance and Zacks Consensus Estimate. 🔮 2026 sales guidance raised to $1.71B-$1.81B, with royalties set to exceed $1B in 2026, a year early. Discover the full growth story here 👉 https://www.zacks.com/stock/news/2825515/halo-rises-nearly-4-on-strong-2025-preliminary-data-and-2026-guidance?cid=sm-stocktwits-2-2825515-body-31029&ADID=SYND_STOCKTWITS_TWEET_2_2825515_BODY_31029
0 · Reply
Sean29md
Sean29md Jan. 29 at 4:28 PM
$HALO part 3: Clearly, Cornnie Johnson did not learn a lesson the first time she was swimming against the current of market participants, other analysts and her own company’s Asset Management Portfolio Manager. Remember her comical analysis today. She will be embarrassed once again when we start trading in $80’s and $90. http://tipranks.com/news/the-fly/h… http://cnbc.com/video/2025/11/…
0 · Reply
Sean29md
Sean29md Jan. 29 at 4:28 PM
$HALO part 2: The answer is no! If anything, there have been new concrete catalysts which will contribute positively to revenue growth in short, medium and long term: 1) new Enhanze approvals (huge new Faspro indications), 2) new Enhanze partnerships which will bring more milestone payments and 3) new delivery platforms (Elektrofi and Surf Bio) This "sell" rating from Goldman Sach's analyst is also at odds with the Greg Tuorto, Goldman Sachs Asset Management portfolio manager who included halozyme in his top 10 holdings when he appeared on CNBC in November . (Watch minute 6:00 on the 2nd link below) This morning, Morgan Stanley maintained its buy rating and raised its target price to $78. Also today, HC Wainwight maintains its buy rating with a price target of $90. Yesterday, TD Cowen reiterated their buy rating with price target of $90.
0 · Reply
Sean29md
Sean29md Jan. 29 at 4:28 PM
$HALO part 1: Goldman Sachs's analyst, Cornnie Johnson downgraded Halozyme to "sell" with price target of $56 on 12/4/25 based on her concern about potential decline in earnings past 2031. Since her 12/4/25 comical analysis, the stock rose from low/mid $60’s to low/mid $70’s. She did not learn her lesson and today reiterated her sell rating with her concern over the rate of revenue growth slowing to 1% after 2029. This is one amateurish downgrade since just a couple of weeks before her 12/4/25 sell rating, she had issued a new "hold" rating (1st link below). Ask yourself this: did anything change that would negatively affect halozyme's future rate of revenue growth (beyond 2031 or beyond 2029 based on her opinion today) during the 2 weeks between her hold rating and her initial downgrade or between her downgrade on 12/4 and today? …
0 · Reply
StocktwitsNews
StocktwitsNews Jan. 28 at 7:37 PM
HALO Stock Edges Up 3% On Upbeat Multi-Year Revenue Guidance, Surf Bio Acquisition $HALO $AVUS $EAOR https://stocktwits.com/news/equity/markets/halo-stock-edges-up-on-upbeat-multi-year-revenue-guidance-surf-bio-acquisition/cmygWBXR408
0 · Reply
Sean29md
Sean29md Jan. 28 at 5:54 PM
$HALO Corinne Johnson (Goldman Sachs), do you care to correct your 12/4/2025 downgrade of Halozyme with a price target of $56 now or do you prefer to wait until we are trading in the $80's and $'90s? You should have a chat with your Goldman Sach's director of asset management who appeared on CNBC with a list of best 2026 stocks which included Halozyme during the same week you issued your downgrade. Remember that course correction is a sign of intelligence!
0 · Reply
Sean29md
Sean29md Jan. 28 at 2:34 PM
$HALO Tour de force, Helen! That was by far the strongest conference call by her since she has been with Halozyme. She is becoming a compelling storyteller. I hope to see her on investment podcasts, CNBC and Bloomberg with the same level of conviction and strength attracting a broader range of investors.
0 · Reply
Swahilipete
Swahilipete Jan. 28 at 11:28 AM
$HALO
0 · Reply
Sean29md
Sean29md Jan. 28 at 1:29 AM
$HALO https://finance.yahoo.com/news/darzalex-faspro-based-quadruplet-regimen-204900267.html
0 · Reply
Sean29md
Sean29md Jan. 27 at 1:19 PM
$HALO Can't argue with facts. See CNBC article below re significance of individual investors. Halozyme's IR just doesn't get it. With chronic near 100% institutional ownership (see second link below), halo's valuations have been consistently suppressed. There has been little true share price discovery for Halozyme compared to industry peers and markets which benefit from a healthy dose of individual investors. Helen needs to appear on investment podcast, YouTube investment channels, CNBC, Bloomberg and tell the growth (now and future) story of halozyme. Storytelling is one of the most important roles of a CEO. Retail investors are reshaping markets. https://www.cnbc.com/2026/01/27/gamestop-meme-stocks-retail-investors-wall-street.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard https://www.nasdaq.com/market-activity/stocks/halo/institutional-holdings
1 · Reply
Itinerant
Itinerant Jan. 25 at 6:05 PM
$HALO In my opinion, this company is a terrific company, very well managed, and significantly under valued (by the numbers....that's what I do...the numbers). I think that the market makers are presently manipulating the stock down because they know (with inside information, as usual), that the company will report a stellar outlook on Wednesday. Such manipulation may seem unlikely with an $8 billion market cap company, but it is not unlikely because the institutions want more, i.e. every share. IMO this company is worth $20 billion, right now. I will buy more tomorrow. JMO
1 · Reply
Sean29md
Sean29md Jan. 20 at 10:41 PM
$HALO https://finance.yahoo.com/news/halozyme-host-investor-conference-call-210500669.html
0 · Reply
TalkMarkets
TalkMarkets Jan. 19 at 9:21 AM
Setting Sail In 2026 Armed With A Complete Rundown Of 2025 Performance And Cash Flows $XAR $HALO $XLK $XLV $XME https://talkmarkets.com/content/global-markets/setting-sail-in-2026-armed-with-a-complete-rundown-of-2025-performance-and-cash-flows?post=550963&userid=166882
0 · Reply
Sean29md
Sean29md Jan. 14 at 4:08 PM
$HALO Where is the 2026 guidance update? For the last 2 years, Halozyme did not present at JPM Healthcare conference (the most popular biopharma conference) but did the investor conference call with annual guidance update. Does the lack of investor call mean that they are so close to signing an MDASE licensing deal with Merck that Helen is waiting to update 2026 EPS guidance until the deal is done?
0 · Reply